Radiation DosageDose-Response Relationship, RadiationRadiation InjuriesGamma RaysRadiation, IonizingAntineoplastic Combined Chemotherapy ProtocolsRadiation ToleranceRadiationChemotherapy, AdjuvantRadiation ProtectionRadiation MonitoringCombined Modality TherapyRadiation OncologyAntineoplastic AgentsTreatment OutcomeRadiotherapyRadiotherapy DosageCisplatinRadiation Injuries, ExperimentalCosmic RadiationRadiation PneumonitisNeoplasms, Radiation-InducedCyclophosphamideRadiometryDoxorubicinBackground RadiationBreast NeoplasmsDrug Administration ScheduleDisease-Free SurvivalNeoplasm StagingUltraviolet RaysTime FactorsSurvival AnalysisRadiation EffectsNeoadjuvant TherapyRadiation-Sensitizing AgentsSurvival RateNeoplasmsDose FractionationRadiation-Protective AgentsEtoposideRadiotherapy, AdjuvantPrognosisNeoplasm Recurrence, LocalRadiotherapy, ConformalMethotrexateAcute Radiation SyndromeRadiotherapy, Intensity-ModulatedBrachytherapyCobalt RadioisotopesDose-Response Relationship, DrugFollow-Up StudiesBrain NeoplasmsPaclitaxelLung NeoplasmsCarboplatinX-RaysRadioactive Hazard ReleaseRadiotherapy Planning, Computer-AssistedRadiobiologyVinblastineDNA DamageBleomycinAdenocarcinomaRadiation Hybrid MappingTomography, X-Ray ComputedAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingInduction ChemotherapyDeoxycytidineTaxoidsCell Line, TumorHead and Neck NeoplasmsLeukemia, Radiation-InducedCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmRadiodermatitisCarcinoma, Squamous CellRelative Biological EffectivenessBody BurdenIfosfamideProspective StudiesHodgkin DiseaseCranial IrradiationWhole-Body IrradiationChemoradiotherapyCell SurvivalLinear Energy TransferSalvage TherapyNeoplasm MetastasisClinical Trials as TopicOrganoplatinum CompoundsApoptosisLymphoma, Non-HodgkinNuclear WarfareDacarbazineAdministration, OralInfusions, IntravenousRadiotherapy, High-EnergyCytarabine